Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9700537 | AMARIN PHARMS | Composition for preventing the occurrence of cardiovascular event in multiple risk patient |
May, 2027
(4 years from now) | |
US9198892 | AMARIN PHARMS | Composition and/or method for preventing onset and/or recurrence of cardiovascular events |
Sep, 2027
(4 years from now) | |
US8440650 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(6 years from now) | |
US8293728 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(6 years from now) | |
US8415335 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(6 years from now) | |
US8546372 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(6 years from now) | |
US8680144 | AMARIN PHARMS | Methods of treating mixed dyslipidemia |
Feb, 2030
(6 years from now) | |
US8518929 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(6 years from now) | |
US8524698 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(6 years from now) | |
US8314086 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(6 years from now) | |
US8318715 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(6 years from now) | |
US8367652 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(6 years from now) | |
US8399446 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(6 years from now) | |
US8431560 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(6 years from now) | |
US8293727 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(6 years from now) | |
US8426399 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(6 years from now) | |
US8377920 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(6 years from now) | |
US8357677 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(6 years from now) | |
US10010517 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(7 years from now) | |
US8445003 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(7 years from now) | |
US8563608 | AMARIN PHARMS | Methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
Apr, 2030
(7 years from now) | |
US11154526 | AMARIN PHARMS | Methods of treating mixed dyslipidemia |
Apr, 2030
(7 years from now) | |
US8623406 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(7 years from now) | |
US8617593 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(7 years from now) | |
US10792267 | AMARIN PHARMS | Methods of treating mixed dyslipidemia |
Apr, 2030
(7 years from now) | |
US10842766 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(7 years from now) | |
US10881632 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(7 years from now) | |
US11103477 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(7 years from now) | |
US8454994 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(7 years from now) | |
US11213504 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(7 years from now) | |
US8298554 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(7 years from now) | |
US8618166 | AMARIN PHARMS | Methods of treating mixed dyslipidemia |
Apr, 2030
(7 years from now) | |
US8642077 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(7 years from now) | |
US8703185 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(7 years from now) | |
US8691871 | AMARIN PHARMS | Methods of treating mixed dyslipidemia |
Apr, 2030
(7 years from now) | |
US8709475 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(7 years from now) | |
US8501225 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(7 years from now) | |
US10265287 | AMARIN PHARMS | Methods of reducing triglycerides and LDL-C |
Apr, 2030
(7 years from now) | |
US8445013 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(7 years from now) | |
US8617594 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(7 years from now) | |
US8551521 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(7 years from now) | |
US10842768 | AMARIN PHARMS | Compositions and methods for lowering triglycerides |
Jun, 2030
(7 years from now) | |
US8710041 | AMARIN PHARMS | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy |
Jun, 2030
(7 years from now) | |
US8669245 | AMARIN PHARMS | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
Jun, 2030
(7 years from now) | |
US8410086 | AMARIN PHARMS | Compositions and methods for lowering triglycerides |
Jun, 2030
(7 years from now) | |
US8455472 | AMARIN PHARMS | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
Jun, 2030
(7 years from now) | |
US11298333 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(10 years from now) | |
US9603826 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(10 years from now) | |
US9610272 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(10 years from now) | |
US9623001 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(10 years from now) | |
US9693984 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(10 years from now) | |
US9693985 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(10 years from now) | |
US9693986 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(10 years from now) | |
US9918954 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(10 years from now) | |
US10278935 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(10 years from now) | |
US10278937 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(10 years from now) | |
US10278936 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(10 years from now) | |
US10383840 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(10 years from now) | |
US10555925 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(10 years from now) | |
US10555924 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(10 years from now) | |
US10568861 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(10 years from now) | |
US10668042 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(10 years from now) | |
US10576054 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(10 years from now) | |
US10792270 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(10 years from now) | |
US10786478 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(10 years from now) | |
US10894028 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(10 years from now) | |
US11000499 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(10 years from now) | |
US11116742 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(10 years from now) | |
US11369582 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Dec 13, 2022 |
Market Authorisation Date: 26 July, 2012
Treatment: Use of vascepa as an adjunct to statin therapy to reduce the occurrence of a cardiovascular event in an adult patient with hypercholesterolemia; Use of vascepa as an adjunct to statin therapy to reduc...
Dosage: CAPSULE;ORAL
169
United States
25
European Union
21
China
18
New Zealand
16
Singapore
16
Canada
14
Korea, Republic of
14
Japan
13
Australia
13
Russia
11
Hong Kong
10
Spain
9
Mexico
8
Denmark
8
Lithuania
8
Slovenia
8
Croatia
8
Portugal
7
Hungary
7
Brazil
7
Poland
6
South Africa
5
Cyprus
5
Malaysia
4
Morocco
4
Philippines
4
Colombia
3
Israel
3
Norway
3
Chile
3
EA
2
Nicaragua
1
Cuba
1
Costa Rica
1
Peru
1
San Marino
1
Dominican Republic
1
RS
1
Ecuador
1
Taiwan, Province of China
1
Luxembourg
1
Georgia
1
Ukraine
1
Tunisia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic